Rilimogene Galvacirepvec

Summary

Rilimogene Galvacirepvec (CHEMBL3039550) is a phase-3 clinical-stage gene; indicated across 3 conditions including prostate adenocarcinoma and prostate carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 3 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3039550
Name	Rilimogene Galvacirepvec
Type	Gene
Max phase	3

Also known as: Prostvac[tm], Prostvac-V, Rilimogen galvacirepvec, Rilimogene galvacirepvec, RILIMOGENE GALVACIREPVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
prostate carcinoma	2	MONDO:0005159	EFO:0001663

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	5
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01322490	PHASE3	COMPLETED	A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
NCT00450463	PHASE2	COMPLETED	Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
NCT01145508	PHASE2	TERMINATED	Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02153918	PHASE2	COMPLETED	Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
NCT02326805	PHASE2	COMPLETED	PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
NCT02649855	PHASE2	COMPLETED	Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
NCT00113984	PHASE1	COMPLETED	Vaccine and Antibody Treatment of Prostate Cancer
NCT03532217	PHASE1	COMPLETED	Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).